Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia - PubMed (original) (raw)

. 2010 Jul;16(7):1068-75.

doi: 10.3201/eid1607.091691.

Biju George, Aeron C Hurt, Joseph S Doyle, Katherine Langan, Alistair B Reid, Janet M Harper, Karin Thursky, Leon J Worth, Dominic E Dwyer, C Orla Morrissey, Paul D R Johnson, Kirsty L Buising, Simon James Harrison, John F Seymour, Patricia E Ferguson, Bin Wang, Justin T Denholm, Allen C Cheng, Monica Slavin

Affiliations

Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia

Adrian R Tramontana et al. Emerg Infect Dis. 2010 Jul.

Abstract

We describe laboratory-confirmed influenza A pandemic (H1N1) 2009 in 17 hospitalized recipients of a hematopoietic stem cell transplant (HSCT) (8 allogeneic) and in 15 patients with malignancy treated at 6 Australian tertiary centers during winter 2009. Ten (31.3%) patients were admitted to intensive care, and 9 of them were HSCT recipients. All recipients of allogeneic HSCT with infection <100 days posttransplantation or severe graft-versus-host disease were admitted to an intensive care unit. In-hospital mortality rate was 21.9% (7/32). The H275Y neuraminidase mutation, which confers oseltamivir resistance developed in 4 of 7 patients with PCR positive for influenza after > or = 4 days of oseltamivir therapy. Three of these 4 patients were critically ill. Oseltamivir resistance in 4 (13.3%) of 30 patients who were administered oseltamivir highlights the need for ongoing surveillance of such resistance and further research on optimal antiviral therapy in the immunocompromised.

PubMed Disclaimer

Figures

Figure

Figure

Date of admission to hospitals in Victoria (A) and New South Wales (B), Australia, for patients with underlying malignancy who were infected with pandemic (H1N1) 2009, April–October 2009. Twelve Victorian and 4 New South Wales patients were recipients of a hematopoietic stem cell transplant. Rates of laboratory detection of all influenza viruses, obtained from population-based epidemic surveillance for Victoria and New South Wales, are given in the Technical Appendix).

Similar articles

Cited by

References

    1. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9:493–504. 10.1016/S1473-3099(09)70175-6 - DOI - PMC - PubMed
    1. Dominguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302:1880–7. 10.1001/jama.2009.1536 - DOI - PubMed
    1. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302:1872–9. 10.1001/jama.2009.1496 - DOI - PubMed
    1. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med. 2009;361:1935–44. 10.1056/NEJMoa0906695 - DOI - PubMed
    1. Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant. 2008;42:637–41. 10.1038/bmt.2008.264 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources